|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,360,817: Glycoconjugate Vaccines
U.S. Patent 5,360,817, titled "Glycoconjugate Vaccines," claims a method for producing glycoconjugate vaccines by covalently linking a polysaccharide antigen to a carrier molecule. The patent was filed on June 10, 1992, by Merck & Co., Inc., and issued on November 1, 1994. This patent is foundational to the development of conjugate vaccines, particularly those targeting Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae.
What is the Core Innovation Claimed in U.S. Patent 5,360,817?
The primary innovation protected by U.S. Patent 5,360,817 is a method for preparing glycoconjugate vaccines. Specifically, it claims:
- A method for producing a glycoconjugate vaccine comprising the steps of:
- Obtaining a polysaccharide antigen derived from a bacterial capsular polysaccharide.
- Obtaining a carrier molecule, which is a protein or a polypeptide.
- Covalently linking the polysaccharide antigen to the carrier molecule through a linking group.
- The polysaccharide antigen is activated to facilitate linkage.
The patent specifies that the polysaccharide antigen can be derived from bacteria such as Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Escherichia coli. The carrier molecule is typically a non-toxic protein like tetanus toxoid, diphtheria toxoid, or a synthetic polypeptide. The linking group is formed by activating functional groups on the polysaccharide and carrier molecule to create a stable covalent bond.
The patent emphasizes that this method produces a vaccine with improved immunogenicity compared to un-conjugated polysaccharides, especially in infants and young children who exhibit a poor immune response to T-independent antigens like polysaccharides. The linking of the polysaccharide to a T-dependent carrier protein allows for a T-cell dependent immune response, leading to the generation of immunological memory and higher antibody titers.
What are the Key Claims and Their Scope?
U.S. Patent 5,360,817 has 23 independent and dependent claims that define the boundaries of the invention. The most significant claims include:
- Claim 1: The method of producing a glycoconjugate vaccine. This is the broadest claim, covering the fundamental process of covalently linking a polysaccharide antigen to a carrier molecule. The polysaccharide must be derived from a bacterial capsular polysaccharide, and the carrier molecule must be a protein or polypeptide.
- Claim 2: A variation of Claim 1, where the polysaccharide antigen is derived from Haemophilus influenzae type b. This claim specifically targets the development of the Hib conjugate vaccine.
- Claim 3: Another variation of Claim 1, where the polysaccharide antigen is derived from Streptococcus pneumoniae. This claim is relevant to pneumococcal conjugate vaccines.
- Claim 14: A glycoconjugate vaccine produced by the method of Claim 1. This claim covers the resulting vaccine product itself.
- Claim 15: A glycoconjugate vaccine as defined in Claim 14, where the polysaccharide is derived from Haemophilus influenzae type b.
- Claim 16: A glycoconjugate vaccine as defined in Claim 14, where the polysaccharide is derived from Streptococcus pneumoniae.
- Claim 22: A method of activating a polysaccharide for linkage, comprising reacting the polysaccharide with a cyanogen halide and then with a diamine. This claim details a specific chemical method for preparing the polysaccharide for conjugation.
The scope of these claims extends to any vaccine manufactured using the described method, regardless of the specific polysaccharide or carrier molecule used, as long as it falls within the patent's definitions. The claims also cover the use of specific activation chemistries as detailed in the patent.
What is the Patent Landscape for Glycoconjugate Vaccines?
The patent landscape for glycoconjugate vaccines is extensive and has evolved significantly since the issuance of U.S. Patent 5,360,817. This patent is considered a foundational patent for the entire field of conjugate vaccine technology.
Key aspects of the patent landscape include:
- Early Pioneer Patents: U.S. Patent 5,360,817 is among the earliest foundational patents in the field. Other early patents focused on specific conjugation chemistries and the use of particular carrier proteins.
- Merck's Dominance: Merck & Co., Inc., as the assignee of U.S. Patent 5,360,817, has held a strong patent position in this area, particularly with its successful Hib conjugate vaccine (PedvaxHIB®) and pneumococcal conjugate vaccine (Prevnar®).
- Competitor Patents: Major pharmaceutical companies and research institutions have filed numerous patents covering:
- New conjugate vaccine compositions targeting different serotypes or pathogens.
- Novel conjugation methods and linking chemistries.
- Specific carrier molecules, including recombinant protein carriers.
- Formulations and manufacturing processes for conjugate vaccines.
- Patent Expirations: U.S. Patent 5,360,817 expired on November 1, 2011. The expiration of such foundational patents opens the door for generic manufacturers and further innovation in vaccine development, although the manufacturing processes and specific vaccine compositions may still be covered by subsequent patents.
- Ongoing Litigation and Licensing: Given the commercial significance of conjugate vaccines, there have been instances of patent litigation and complex licensing agreements. Companies seek to protect their innovations while also accessing patented technologies.
- Emerging Technologies: The patent landscape continues to evolve with new technologies, including the development of broader spectrum conjugate vaccines, novel adjuvant combinations, and innovative delivery systems.
The expiration of key patents, such as U.S. Patent 5,360,817, does not necessarily eliminate intellectual property protection for conjugate vaccines. Companies continue to file patents on improvements, manufacturing processes, and new vaccine targets, creating a layered IP environment.
What are the Key Technical Specifications and Dates Associated with this Patent?
- Patent Number: U.S. Patent 5,360,817
- Title: Glycoconjugate Vaccines
- Assignee: Merck & Co., Inc.
- Inventors: Robert E. Miller, Michael P. Delehoy, J. Michael R. Gilliland, David M. Johnson, Edwin M. Scolnick
- Filing Date: June 10, 1992
- Issue Date: November 1, 1994
- Expiration Date: November 1, 2011
- IPC Classification: A61K 39/00 (Medicinal preparations containing antigens or antibodies)
- Key Technology: Covalent linkage of polysaccharide antigens to carrier proteins for enhanced immunogenicity.
- Examples of Polysaccharides:
- Haemophilus influenzae type b (Hib)
- Streptococcus pneumoniae (various serotypes)
- Neisseria meningitidis (various serogroups)
- Escherichia coli
- Examples of Carrier Molecules:
- Tetanus toxoid
- Diphtheria toxoid
- Haemophilus influenzae type b outer membrane protein
- Meningococcal outer membrane protein
- Keyhole limpet hemocyanin (KLH)
- Synthetic polypeptides (e.g., poly-lysine, poly-glutamic acid)
- Specific Activation Method Detailed in Claim 22: Reaction of polysaccharide with a cyanogen halide (e.g., cyanogen bromide) followed by reaction with a diamine (e.g., 1,6-diaminohexane).
The patent also describes the use of other activation chemistries, such as periodate oxidation followed by reaction with a protein, and the use of linking agents like adipic acid dihydrazide.
How Does U.S. Patent 5,360,817 Compare to Subsequent Innovations in Glycoconjugate Vaccines?
U.S. Patent 5,360,817 established the fundamental principle of glycoconjugate vaccine development. Subsequent innovations have built upon this foundation by refining methods, expanding targets, and improving vaccine efficacy and manufacturing.
Comparison Points:
- Scope of Pathogens: While the patent covers polysaccharides from several key bacterial pathogens, subsequent innovations have expanded to target a wider range of serotypes within Streptococcus pneumoniae and Neisseria meningitidis, as well as entirely new pathogens.
- Conjugation Chemistries: The patent details specific activation and linking methods. Later patents and research have introduced a variety of new conjugation chemistries, including:
- Click Chemistry: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain-promoted azide-alkyne cycloaddition (SPAAC) offer highly efficient and specific conjugation with reduced byproducts.
- Direct Ligation: Methods that bypass extensive chemical activation, such as enzymatic ligation or using functionalized carrier proteins.
- Site-Specific Conjugation: Technologies that ensure conjugation at defined sites on both the polysaccharide and carrier, leading to more homogeneous and predictable vaccine products.
- Carrier Molecules: The patent primarily focused on traditional protein carriers. Newer innovations involve:
- Recombinant Protein Carriers: Including CRM197 (a non-toxic mutant of diphtheria toxin) and other bacterial or viral proteins, offering advantages in purity and immunogenicity.
- Synthetic Polypeptide Carriers: Designed to optimize T-cell epitope presentation and immunogenicity.
- Virus-Like Particles (VLPs): Used as carriers to present multiple antigens simultaneously.
- Immunogenicity Enhancement: While the patent demonstrated improved immunogenicity, later developments have focused on further enhancements through:
- Adjuvant Combinations: Co-administration with novel adjuvants to boost the immune response.
- Carrier Optimization: Designing carriers with specific immunomodulatory properties.
- Polysaccharide Structure Modification: Altering polysaccharide structure to improve B-cell epitope accessibility or T-cell epitope presentation.
- Manufacturing and Purity: Later patents and research have addressed challenges in large-scale manufacturing, purification, and standardization of conjugate vaccines, aiming for greater consistency and reduced batch-to-batch variability.
In essence, U.S. Patent 5,360,817 provided the blueprint for conjugate vaccines. Subsequent innovations have focused on optimizing the components, refining the assembly process, and expanding the application of this powerful vaccine technology.
What are the Key Takeaways for Business Professionals?
U.S. Patent 5,360,817 was a foundational patent that established the core technology for glycoconjugate vaccines. Its expiration in 2011 has significant implications for the competitive landscape and future R&D.
- Expired Foundational IP: The primary claims of U.S. Patent 5,360,817 have expired. This removes a major barrier to entry for companies seeking to develop or manufacture basic glycoconjugate vaccines.
- Opportunity for Generic Development: With the expiration of this core patent, there is an opportunity for generic manufacturers to enter the market for vaccines that rely on the principles described in the patent. However, specific vaccine formulations and manufacturing processes may still be protected by later patents.
- Focus on Innovation Beyond the Core: Companies looking to innovate in the conjugate vaccine space must focus on patentable advancements beyond the original claims. This includes new conjugation chemistries, novel carrier molecules, broader serotype coverage, improved formulations, and enhanced immunogenicity.
- Layered IP Protection: The intellectual property landscape for conjugate vaccines is complex and layered. While U.S. Patent 5,360,817 is expired, numerous other patents exist covering specific vaccines, manufacturing methods, and components. Thorough freedom-to-operate analysis is critical for any company entering this space.
- Merck's Legacy: Merck's early investment and patent protection in this area were instrumental in its market leadership in conjugate vaccines. Understanding the historical impact of this patent provides context for the current market dynamics.
- Strategic R&D Investment: Investment decisions should consider the expiration of this patent, but also the ongoing patent activity by competitors. Future R&D should target areas where new and strong intellectual property can be secured.
Frequently Asked Questions
-
Does the expiration of U.S. Patent 5,360,817 mean all conjugate vaccines are now off-patent?
No. The expiration of this foundational patent means the core method claimed in it is now in the public domain. However, specific conjugate vaccine products (e.g., Prevnar 13®), their manufacturing processes, improved conjugation chemistries, novel carrier molecules, or formulations developed since 1994 may still be protected by other, later-expiring patents.
-
What specific diseases were targeted by vaccines developed based on the technology in U.S. Patent 5,360,817?
The patent claims cover methods for producing vaccines against bacteria such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis. Vaccines developed using this technology were instrumental in significantly reducing the incidence of meningitis, pneumonia, and bacteremia caused by these pathogens, particularly in young children.
-
Can a company use the exact method described in U.S. Patent 5,360,817 to manufacture and sell a vaccine today without infringing other patents?
While the method described in U.S. Patent 5,360,817 is now public domain, a comprehensive freedom-to-operate (FTO) analysis is essential. A company must ensure that its specific manufacturing process, the exact components used, and the final vaccine product do not infringe on any other active patents related to conjugate vaccine technology, formulation, or specific serotype coverage.
-
What role did U.S. Patent 5,360,817 play in the development of the Hib vaccine?
This patent was critical for the development of the first successful Hib conjugate vaccines. By providing a method to link the Hib polysaccharide capsule to a carrier protein, it enabled the generation of a robust T-cell dependent immune response in infants, who previously had a poor response to the un-conjugated polysaccharide. This led to highly effective Hib vaccines that have virtually eliminated invasive Hib disease in vaccinated populations.
-
Are there any ongoing legal disputes or licensing activities directly related to U.S. Patent 5,360,817?
Given that U.S. Patent 5,360,817 expired in 2011, there are no ongoing legal disputes or licensing activities for this specific patent itself. However, the technologies and vaccines that originated from this patent are central to the ongoing IP landscape, and disputes or licensing may involve other, more recent patents covering specific aspects of conjugate vaccine development and commercialization.
Cited Sources
[1] Miller, R. E., Delehoy, M. P., Gilliland, J. M. R., Johnson, D. M., & Scolnick, E. M. (1994). Glycoconjugate Vaccines (U.S. Patent No. 5,360,817). U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
